Announcement on behalf of OBIGEN that the BOD resolved to issue 2024 employee stock options and the subscription rules.
2024.Mar.20
Announcement on behalf of OBIGEN that the BOD resolved to convene the 2024 Annual General Shareholders' Meeting
2024.Mar.11
Announcement of BOD’s resolution to lift the non-competition restrictions for managerial officers
2024.Mar.11
Announcement of 2023 Consolidated Financial Statements were approved by the Board of Directors
2024.Mar.11
The Company's Board of Directors resolved to convene the 2024 Annual General Shareholders' Meeting
2024.Mar.11
Announcement of not Distributing Dividends in 2023
2024.Mar.11
OBI announces the termination of OBI-3424-001 trial while continuing the collaboration of OBI-3424 with partners
2024.Feb.29
Announcement on behalf of OBIGEN that it has filed the application of Phase II human clinical trial for OBI-858 to TFDA
2024.Jan.31
Adagloxad Simolenin (OBI-822)/OBI-821, receives a positive 1st interim analysis recommendation, suggesting the continuation of the Phase III TNBC trial
2024.Jan.03
OBI-992 TROP2 ADC has been granted by US FDA to proceed to Phase I/II human clinical trial
